CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED FEBRUARY 28, 2017 (EXPRESSED IN CANADIAN DOLLARS)

(UNAUDITED - PREPARED BY MANAGEMENT)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED – PREPARED BY MANAGEMENT) AS AT

	F	February 28, 2017		
ASSETS				
Current				
Cash	\$	21,600	\$	135,688
Receivables (Note 7)		56,979		76,114
Prepaid expenses (Note 8)		35,486		61,500
Total current assets		114,065		273,302
Reclamation bonds (Note 9)		5,040		5,040
Intangible assets (Note 10)		25,100		25,100
Total assets	\$	144,205	\$	303,442
LIABILITIES AND SHAREHOLDERS' EQUITY				
Current				
eurient				
Accounts payable and accrued liabilities (Notes 12 and 14)	\$	580,861	\$	
	\$	580,861 426	\$	
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13)	\$		\$	347,406 426 347,832
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13) Fotal liabilities Shareholders' deficiency	\$	426 581,287	\$	426
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13) Fotal liabilities Shareholders' deficiency Capital stock (Note 15)	\$	426	\$	426 347,832 9,670,847
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13) Total liabilities Shareholders' deficiency Capital stock (Note 15) Shares held in treasury (Note 10)	\$	426 581,287 9,715,872	\$	426 347,832 9,670,847 (255,000)
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13) Total liabilities Shareholders' deficiency Capital stock (Note 15) Shares held in treasury (Note 10) Reserves		426 581,287 9,715,872 1,218,158	-	426 347,832 9,670,847 (255,000) 800,758
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13) Total liabilities Shareholders' deficiency Capital stock (Note 15) Shares held in treasury (Note 10)		426 581,287 9,715,872	-	426 347,832 9,670,847 (255,000) 800,758
Accounts payable and accrued liabilities (Notes 12 and 14) Loans payable (Note 13) Total liabilities Shareholders' deficiency Capital stock (Note 15) Shares held in treasury (Note 10) Reserves		426 581,287 9,715,872 1,218,158	-	426

On behalf of the Board:

"Gabriel Napora", Director *"Colin Wiebe"*, Director

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED – PREPARED BY MANAGEMENT) FOR THE

	ree months ended February 28, 2017		ree months ended bruary 29, 2016	Six months ended February 28, 2017	Ι	Six months ended February 29, 2016
REVENUE Production income	\$ 37,024	\$	-	\$ 98,524	\$	-
Production expenses	(26,838)		-	(66,752)		-
	10,186		-	31,772		-
EXPENSES						
Consulting fees and management fees (Note 14)	172,320		51,490	303,775		145,240
Foreign exchange loss	3,473		8	5,985		325
Interest expense	280		(40)	280		8,360
Net profits interests acquired	-		-	228,600		-
Office, rent, and miscellaneous	7,149		1,647	16,858		6,617
Professional fees	26,165		21,830	42,104		48,268
Realized loss on marketable securities	-		-	-		34,553
Share-based compensation (Note 15)	417,400		-	417,400		-
Shareholder communications and promotion	24,416		-	42,548		4,304
Transfer agent and filing fees	15,688		4,926	22,136		9,844
Travel and accommodation	7,621		-	62,203		19,000
Unrealized loss on marketable securities	-		-	-		15,000
	674,512		-	1,141,889		-
Total loss and comprehensive loss for the period	\$ (664,326)	\$	(79,861)	\$ (1,110,117)	\$	(291,511)
Basic and diluted net loss per common share	\$ (0.02)	\$	(0.01)	\$ (0.03)	\$	(0.03)
Weighted average number of common shares outstanding – basic and diluted	39,262,103	1	1,074,263	38,908,021		11,074,263

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED – PREPARED BY MANAGEMENT) FOR THE SIX MONTHS ENDED,

		February 28, 2017		February 29, 2016	
CASH FLOW FROM OPERATING ACTIVITIES					
Net loss for the period	\$	(1, 110, 117)	\$	(291,511)	
Items not affecting cash:					
Interest accrued on loans payable		-		276	
Realized loss on marketable securities		-		34,553	
Share-based compensation		417,400	-		
Unrealized loss on marketable securities		-	15,000		
Change in non-cash working capital items:					
Decrease in receivables		19,135		773	
Decrease in prepaid expenses		26,014		10,000	
Increase in accounts payable and accrued liabilities		304,880		119,531	
Net cash flows used in operating activities		(342,688)		(111,378)	
CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from option exercises		-		3,000	
Subscriptions received in advance		-		41,500	
Net cash flows provided by financing activities	<u> </u>	-		44,500	
CASH FLOWS FROM INVESTING ACTIVITIES Net profits interests acquired		228,600		-	
Proceeds from sale of marketable securities				75,447	
Net cash flows provided by investing activities		228,600		75,447	
Change in cash		(114,088)		8,569	
Cash, beginning of period		135,688		2,195	
Cash, end of period	\$	21,600	\$	10,764	
Cash paid for taxes during the period	\$	-	\$	-	
Cash paid for interest during the period	\$	_	\$	-	

Supplemental disclosure with respect to cash flows (Note 16)